Evaluation of Outcomes and Regression after Neovascularization Treatment for Non-type 1 Retinopathy of Prematurity

Introduction: To study the unfavorable outcomes and regression after neovascularization treatment for non-type 1 retinopathy of prematurity (ROP) in a tertiary care facility Thailand. Methods: A retrospective was done all infants undergoing screening ROP at referral center between July 2018 June 2021 with follow-up 60 weeks postmenstrual ages (PMA). The measured were outcomes, including macula involving posterior retinal folds, detachment, retrolental cicatrix formation, or mass obscuring view pole, treatment. received (stage 3 ROP) within 72 h diagnosis. also compared type subgroups. Results: There 58 eyes 31 that included study. Of these eyes, 41 had ROP, 17 ROP. 92.68% treated stage zone II pre-plus disease 74.47% plus disease. mean gestational age birth weight enrolled 28.48 ± 1.99 1165.32 394.57 g, respectively. Unfavorable occurred three (17.65%) group, but there no group (p=0.022); laser indirect ophthalmoscopy (LIO) combined Intravitreal bevacizumab (IVB). LIO alone 100% regression, whereas IVT 82.35% regression. Progression without five (29.41%) progression (p=0.001). Conclusion: Neovascularization is useful preventing achieving neovascularization, especially diseases less severe than Moreover, can reduce